The London Seed Capital investment fund, the London Business Angels and the Catapult Venture Managers have awarded Michelson Diagnostics Ltd. of Orpington, UK, £600,000 of early-stage funding to pursue in vivo clinical trials of real-time cancer imaging technology. The project aims to enable faster and more accurate cancer surgeries. With the technology, the company expects that surgeons will be able to see a tumor’s size and location, assess its margin and spread, and create better outcomes.